Individualizing pharmacologic and non-pharmacologic therapy for CKD associated with diabetes.

Abstract

Diabetic kidney disease (DKD) now has more proven kidney-protective therapies than at any previous time: renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) finerenone. However, no head-to-head randomized controlled trial (RCT) has compared these classes, no Phase 3 trial has confirmed that specific multi-class combinations improve hard outcomes beyond well-selected monotherapy; and long-term safety of sustained combination therapy has not been fully characterized. This review synthesizes contemporary evidence for kidney-protective therapy in adults with DKD, emphasizing that non-pharmacologic measures-blood pressure control, individualized glycemic targets, sodium and protein moderation, structured exercise, weight management, and smoking cessation-should be intensified concurrently with drug therapy. We propose an individualization framework that selects agents whose mechanisms address more than one of the patient's clinical problems simultaneously and avoids those whose adverse effects conflict with active comorbidities. Combination therapy is biologically rational and supported by additive albuminuria reduction (CONFIDENCE) and lifetime modeling, but hard-outcome confirmation is absent. Until such trials are available, the most defensible framework is an individualized, monitoring-based strategy that adapts through addition, hold, or deprescribing based on clinical evolution.